Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

M Annala; S Fu; JVW Bacon; J Sipola; N Iqbal; C Ferrario; M Ong; D Wadhwa; SJ Hotte; G Lo; B Tran; LA Wood; JR Gingerich; SA North; CJ Pezaro; JD Ruether; SS Sridhar; HML Kallio; DJ Khalaf; A Wong; K Beja; E Schönlau; S Taavitsainen; M Nykter; G Vandekerkhove; AA Azad; AW Wyatt; KN Chi

Journal article

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, G Lo, B Tran, LA Wood, JR Gingerich, SA North, CJ Pezaro, JD Ruether, SS Sridhar, HML Kallio, DJ Khalaf, A Wong Show all

Ann Oncol | Published : 2021

DOI: 10.1016/j.annonc.2021.03.205

Abstract

BACKGROUND: Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI). We sought to determine optimal treatment in this setting. PATIENTS AND METHODS: This multicentre, randomised, open-label, phase II trial recruited patients with ARPI-naive mCRPC and poor prognosis features (presence of liver metastases, progression to mCRPC after <12 months of androgen deprivation therapy, or ≥4 of 6 clinical criteria). Patients were randomly assigned 1 : 1 to receive cabazitaxel plus prednisone (group A) or physician's choice of enzalutamide or abiraterone plus prednisone (group B) at standard doses. Pa..

View full abstract